DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more

DiaSys Showcases High Quality Diagnostic Reagents and System Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023

Image: DiaSys is present at MEDICA 2023 at Stand F80 in Hall 3 (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its comprehensive portfolio of clinical chemistry analyzers, reagents, calibrators and controls at MEDICA 2023.

DiaSys offers complete system solutions including analyzer, reagents, and software. At MEDICA 2023, DiaSys is highlighting the respons910 benchtop analyzer which has a throughput of 100 to 150 tests/hour and is ideal for laboratories with a test volume of up to 500 tests per shift. Its high onboard capacity of 30 different methods in mono- or twin-containers and 30 sample positions offers the necessary flexibility for everyday use. Alongside the respons910, DiaSys is showcasing the respons920 benchtop analyzer with higher speed and guaranteed throughput of 200 tests/h and 360 tests/hour with ISE. With an on-board capacity of 30 different methods in mono- or twin containers, 30 samples plus nine positions for calibrators, controls, or emergency samples, respons920 offers almost unlimited flexibility in organizing laboratory workflows.

DiaSys is also highlighting the respons940 automated random access clinical chemistry analyzer that offers a constant throughput of a minimum of 400 tests/h, independent of whether a mono- or two-component reagent is used. Together with modern software features, pre-programmed applications, and carry-over evasion lists, respons940 analyzer delivers high-quality results for a broad parameter portfolio. Among the company’s products being highlighted at the show is the DiaSys CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls that allow true differentiation of borderline cases. DiaSys has extended its cardiovascular risk assessment portfolio with two innovative new reagents, HDL-c direct FS and LDL-c direct FS. Both are homogenous assays for direct determination. DiaSys has also expanded the application range for its Total bile acids 21 FS reagent and now offers the assay for use in serum and stool samples.

Related Links:
DiaSys Diagnostic Systems